优化精神分裂症抗精神病药治疗策略:发现可增强药物反应预测的遗传生物标志物
基于3269例中国精神分裂症患者的大规模全基因组关联研究,患者接受奥氮平、利培酮、阿立哌唑、喹硫平或氨磺必利单药治疗8周。将反应分为高、中、低三组后,在CDH12、WDR11和ELAVL2附近或内部发现三个新显著关联遗传位点,并建立各药物反应预测模型,准确率79.5%至98.0%。
要点
- 3269例中国精神分裂症患者接受五种单药抗精神病药治疗8周。
- 在CDH12、WDR11和ELAVL2附近或内部发现三个新显著关联遗传位点。
- 各药物反应预测模型准确率范围为79.5%至98.0%。
核心结论
- 研究建立了一种有效方法,可跨三个类别预测精神分裂症患者对拉精神病药的反应,整合新生物标志物以指导个性化医疗策略。
研究设计与样本
- 基于3269例中国精神分裂症患者的大规模全基因组关联研究,每名参与者接受奥氮平、利培酮、阿立哌唑、喹硫平或氨磺必利五种单药抗精神病药之一的8周治疗方案。
主要发现
- 将反应分为「高」「中」「低」有序组别以减轻治疗结局不明确的偏倚后,在CDH12、WDR11和ELAVL2附近或内部识别出三个新显著关联遗传位点。
- 针对每种特定抗精神病药开发了反应预测模型,准确率范围为79.5%至98.0%。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Schizophrenia (SCZ) is a severe mental disorder affecting around 1% of individuals worldwide. The variability in response to antipsychotic drugs (APDs) among SCZ patients presents a significant challenge for clinicians in determining the most effective medication. In this study, we investigated the biological markers and established a predictive model for APD response based on a large-scale genome-wide association study using 3269 Chinese schizophrenia patients. Each participant underwent an 8-week treatment regimen with one of five mono-APDs: olanzapine, risperidone, aripiprazole, quetiapine, or amisulpride. By dividing the response into ordinal groups of "high", "medium", and "low", we mitigated the bias of unclear treatment outcome and identified three novel significantly associated genetic loci in or near CDH12, WDR11, and ELAVL2. Additionally, we developed predictive models of response to each specific APDs, with accuracies ranging from 79.5% to 98.0%. In sum, we established an effective method to predict schizophrenia patients' response to APDs across three categories, integrating novel biomarkers to guide personalized medicine strategies.
引用
- Chen L, Huai C, Song C, et al. Refining antipsychotic treatment strategies in schizophrenia: discovery of genetic biomarkers for enhanced drug response prediction. Mol Psychiatry. 2024. PMID: 39562719. doi:10.1038/s41380-024-02841-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。